Nephrotoxicity Biomarker Prepares For Clinic After FDA Blesses Animal Test
Executive Summary
The firms that obtained FDA/EMEA qualification of seven nephrotoxicity biomarkers for preclinical drug testing are midway through development of a protocol to test their efficacy in a clinical trial
You may also be interested in...
Drug Development Tools: Passed And Future
FDA has qualified a total of eight biomarkers submitted by two different consortia through a process that has followed, to varying degrees, the route described in the recently released draft guidance on drug development tool qualification.
BIO Teams With Zerhouni On Quest For "New Big Ideas" To Speed Development
BIO CEO Jim Greenwood is looking for "new big ideas" that would enable the pharmaceutical industry "to accelerate the pace of progress from academic research and translational research into products.
BIO Teams With Zerhouni On Quest For "New Big Ideas" To Speed Development
BIO CEO Jim Greenwood is looking for "new big ideas" that would enable the pharmaceutical industry "to accelerate the pace of progress from academic research and translational research into products.